Home » Newsletters » BioWorld Science

BioWorld Science

July 8, 2020

View Archived Issues

Noncoding mutations contribute to heart disease

Good vs. evil in the synovial joint

Topline data presented from global phase II trial of SEP-4199 in bipolar I depression

Discovery of novel HDAC6 selective inhibitors with potent preclinical activity

ImmunoGen presents next-generation FR-alpha-targeting ADC, IMGN-151

Dana-Farber Cancer Institute presents new MAPK9 inhibitors

Theravance Biopharma patents TGFR-1 inhibitors

Prelude Therapeutics discloses Mcl-1 inhibitors

RemeGen describes new angiogenesis inhibitors

ImmuneOnco Biopharmaceuticals divulges anti-PD-L1 and anti-VEGF compounds

Enrollment completed in pivotal DERBY and OAKS studies of pegcetacoplan

Novel innovative COVID-19 drug testing platform launched in the U.K.

Cabaletta Bio and Artisan Bio collaborate to develop next-generation CAAR T-cell therapies

Engineered interleukin-18 ignores tumors' defenses

Potent, orally available AXL inhibitor DW-17401 reduces xenograft tumor growth

Anti-CCR8 MAb BMS-986340 shows promise as cancer immunotherapeutic

Allogeneic anti-PTK7 CAR-T cells may allow safe access to the anticancer target

New phase I trial evaluates Curis' IRAK-4 kinase inhibitor CA-4948 in AML and MDS

Pivotal study of F-627 for chemotherapy-induced neutropenia meets primary and secondary endpoints

Anti-HER3 antibody shows efficacy in vivo against NRG1 fusion-bearing tumors

Inqovi approved in U.S. and Canada for MDS

InMed begins second phase I trial of INM-755 for epidermolysis bullosa

GSK and Medicago collaborate on adjuvanted COVID-19 candidate vaccine

STK-001 studied for Dravet syndrome in new phase I/II study

Corvus begins phase I study of CPI-006 in COVID-19

Hepion reports promising preclinical data with CRV-431 supporting potential for COVID-19

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 3, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...